Hutch News

Hutch News

Stories tagged 'Transplant and Immunotherapy'

Science to watch in 2018: From immunotherapy to gene therapy, big data to new tech

Fred Hutch experts lend their predictions for the coming year’s advances

Jan. 12, 2018 | By Rachel Tompa / Fred Hutch News Service

We asked Fred Hutch researchers for their predictions on scientific advances to watch in the coming year. Look for their tips on what's next in cancer immunotherapy, precision oncology, gene editing, infectious disease research, cancer prevention and more.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Jan. 4, 2018

Increasing access to stem cell transplants; improving survival, QOL for those with scleroderma; biostatistician named chair-elect of AAAS Section on Statistics.

View story >

10 highlights of Fred Hutch science in 2017

A look back at notable discoveries in cancer immunotherapy, HIV prevention and more

Dec. 28, 2017 | by Sabin Russell and Susan Keown / Fred Hutch News Service

It's been a year of breakthroughs at Fred Hutch. Here are 10 of our favorites.

View story >

Fred Hutch/SCCA transplant patient survival above the expected rate in U.S.

For 5th year in a row, bone marrow transplant program receives top recognition

Dec. 22, 2017 | By Molly McElroy

For the fifth year in a row, the Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has been recognized by the Center for International Blood and Marrow Transplant Research as exceeding expectations for one-year survival rates. These survival rates specifically pertain to patients who have received transplants of blood-forming stem cells from healthy donors, a procedure pioneered at Fred Hutch.

View story >

Good News at Fred Hutch

Celebrating faculty and staff achievements

Dec. 14, 2017

Fred Hutchinson Cancer Research Center has announced awards totaling $1 million to nine of its scientists through the Evergreen Fund, a unique grant program that supports homegrown research projects deemed attractive to potential commercial partners. This is the second year of Evergreen Fund awards. This is the second year of Evergreen Fund awards. The Hutch’s Business Development & Strategy office created the program in 2016 in an effort to encourage scientists to pursue creative ideas with commercial appeal. The goal is to speed research from the bench to the bedside while generating income from patent rights and partnerships with the business sector.

View story >

New insights into CAR T-cell therapy's potential side effects

Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer

Dec. 11, 2017 | By Fred Hutch staff

Detailed studies of two potential side effects of an emerging cancer immunotherapy could eventually help make this strategy, CAR T-cell therapy, safer for patients. The studies examined cytokine release syndrome and neurologic toxicities.

View story >

(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks


Support our quest for cures

Story Archive


Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers

Fred Hutch News

        Get updates via email.